S. N. Atkinson

AN OPEN, RANDOMISED, PARALLEL GROUP STUDY OF LACTULOSE VERSUS ISPAGHULA IN THE TREATMENT OF CHRONIC CONSTIPATION IN ADULTS

P. Prescott, M. Mahapatra, M. Grillage, 1991, The British journal of clinical practice.

The 12‐month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro‐oesophageal reflux disease

D. Peura, S. N. Atkinson, M. C. Perez, 2011, Alimentary pharmacology & therapeutics.

Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non‐erosive reflux disease

W. Chey, R. Fass, S. Zakko, 2009, Alimentary pharmacology & therapeutics.

Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed‐release formulation – results from two randomized controlled studies

P. Sharma, N. Shaheen, D. Peura, 2009, Alimentary pharmacology & therapeutics.

Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis – maintenance of healing and symptom relief

C. Howden, R. Palmer, C. Howden, 2009, Alimentary pharmacology & therapeutics.

Sleeve gastrectomy prevents hypertension associated with unique shifts in the gut microbiome

T. Kindel, J. Kirby, M. Barron, 2020, Surgical Endoscopy.

Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed‐release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis

D. Metz, L. Larsen, C. Howden, 2009, Alimentary pharmacology & therapeutics.